<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00368082</url>
  </required_header>
  <id_info>
    <org_study_id>17946-TGFBeta</org_study_id>
    <secondary_id>TGF-beta</secondary_id>
    <nct_id>NCT00368082</nct_id>
    <nct_alias>NCT00675571</nct_alias>
  </id_info>
  <brief_title>Autologous/Allogeneic TGFbeta-resistant LMP-specific CTL, Lymphoma (TGF-beta)</brief_title>
  <acronym>TGF-beta</acronym>
  <official_title>Administration of TGF-b Resistant LMP-Specific Cytotoxic T-Lymphocytes to Patients With Relapsed EBV-Positive Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Baylor College of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Texas Children's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Methodist Hospital System</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Center for Cell and Gene Therapy, Baylor College of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Baylor College of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients have a type of lymph gland cancer called HD, NHL or lymphoepithelioma (these 3
      diseases will be referred to as &quot;Lymphoma&quot;). The lymphoma has come back or has not gone away
      after treatment (including the best treatment known for these cancers). This is a research
      study using special immune system cells called TGFb-resistant LMP-specific cytotoxic T
      lymphocytes (DNR-CTL), a new experimental therapy.

      Some patients with Lymphoma show signs of infection with the virus that causes infectious
      mononucleosis Epstein Barr virus (EBV) before or at the time of their diagnosis of the
      Lymphoma. EBV is found in the cancer cells of up to 1/2 the patients with Lymphoma,
      suggesting it may play a role in causing Lymphoma. The cancer cells infected by EBV are able
      to hide from the body's immune system and escape being killed by releasing a substance called
      Transforming Growth Factor-beta (TGFb). The investigators want to see if special white blood
      cells (called T cells) that have been given a gene that they hope will let them survive
      against TGFb and that have been trained to kill EBV infected cells can also survive in the
      blood and kill the tumor.

      Investigators have used this sort of therapy with specially trained T cells to treat a
      different type of cancer that occurs after bone marrow and solid organ transplant called post
      transplant lymphoma. In this type of cancer they were able to successfully prevent and treat
      post transplant lymphoma. However when they used a similar approach in HD some patients had a
      partial response to this therapy, but no patients had a complete response. In a follow-up
      study they tried to find out if they could improve this treatment by growing T cells that
      recognize 2 of the proteins expressed on Lymphoma cells called LMP-1 and LMP2a. These special
      T cells were called LMP-specific cytotoxic T-lymphocytes (CTLs). Although some patients had
      tumor responses, CTL therapy alone did not cure those who had a lot of disease. Investigators
      think that a reason for this is that the tumor cells are releasing TGFb (a substance that
      inhibits the growth and function of CTLs). For this reason, they want to find out if they can
      make the CTL resistant to TGFb by putting in a new gene called TGFb resistance gene.
      Investigators hope but don't know that this will improve this treatment for relapsed
      lymphoma. These TGFb-resistant LMP-specific CTLs are an investigational product not approved
      by FDA.

      The purpose of this study is to find the largest safe dose of TGFb resistant LMP-specific
      CTLs, to learn what the side effects are and to see whether this therapy might help patients
      with HD, NHL and lymphoepithelioma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Investigators will test a biopsy of the tumor to see if the tumor cells are EBV positive and
      to see if the subject is eligible for this study. Then they will take some blood from the
      donor, which is used to grow T cells. First they will grow a special type of cell called
      dendritic cells (or monocytes), which stimulates the T cells and add a specially produced
      human adenovirus that carries the LMP1 and LMP-2a genes into the dendritic cells(or
      monocytes). Addition of a gene to the cells is known as gene transfer. These dendritic cells
      (or monocytes) are then used to stimulate T cells. The stimulation trains the T cells to kill
      cells with LMP on their surface. Investigators will then make more LMP-specific CTLs by
      stimulating them with EBV infected cells (which we will make from the subject's blood or the
      donor's blood by infecting them with EBV in the laboratory). They also will put the
      adenovirus that carries the LMP1 and LMP2 genes into these EBV infected cells so that they
      increase the amount of LMP1 and LMP2, which these cells have.

      These EBV infected cells are treated with radiation so they cannot grow. Once sufficient
      numbers of T cells are made, investigators test them to see if they kill cells with LMP on
      their surface. To make sure that these cells won't attack the subjects tissues they test the
      cells against the skin cells or against T cells that they grow in the laboratory.

      To make these CTL resistant to the effects of the TGFb released by the tumor we put in a new
      gene called a mutant TGFb receptor. Investigators used a mouse retrovirus that had been
      changed to stop it from causing infection to add the mutant TGFb receptor to the cells.

      WHAT THE INFUSION WILL BE LIKE:

      After the cells are made, they will be frozen. If the subject agrees to participate in this
      study, at the time they are scheduled to be treated, the cells will then be thawed and
      injected into the subject over 10 minutes.

      Initially two doses of T cells will be given two weeks apart. If after the second infusion,
      there is a reduction in the size of the subject's lymphoma (or no increase) on CT or MRI
      scans as assessed by a radiologist, the subject can receive up to six additional doses if it
      would be to their benefit, if they would like to receive more doses, and if there is enough
      product remaining to give them additional doses.

      This is a dose escalation study as investigators don't know what the highest dose of T cells
      with the new gene is safe. To find out, they will give the cells to 2 participants at one
      dose level. If that is safe they will raise the dose given to the next group of participants.
      The dose the subject will get will depend on how many participants get the agent before and
      how they react. The investigator will tell the subject this information.

      All of the Treatments will be given by the Center for Cell and Gene Therapy at Texas
      Children's Hospital or Houston Methodist Hospital.

      FOLLOW-UP STUDIES We will follow the subject after the injections. Total time participation
      for this study will be 15 years.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>April 2006</start_date>
  <completion_date type="Anticipated">July 2031</completion_date>
  <primary_completion_date type="Actual">September 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and MTD of 2 IV injections of autologous/syngeneic or allogeneic TGFb resistant LMP-specific cytotoxic T-lymphocytes.</measure>
    <time_frame>6 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Survival and immune function of TGFbeta-resistant LMP-specific cytotoxic T-lymphocytes</measure>
    <time_frame>15 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>determine anti-viral and anti-tumor effects of TGFbeta resistant LMP-specific CTL</measure>
    <time_frame>15 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Lymphoma</condition>
  <condition>Hodgkin's Disease</condition>
  <condition>Relapse</condition>
  <condition>Lymphoma, Non-Hodgkin</condition>
  <arm_group>
    <arm_group_label>TGFbeta resistant LMP-specific CTLs</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CTLs be given by intravenous injection over 1-10 minutes through either a peripheral or a central line.
If patients with active disease have stable disease or a partial response at their 6 week or subsequent evaluations they will be eligible to receive up to 6 additional doses of CTLs at 1-2 monthly intervals-each of which will consist of the same cell number as their second injection.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>TGFbeta resistant LMP-specific CTLs</intervention_name>
    <description>Each patient will receive 2 injections, 14 days apart, according to the following dosing schedules:
Group One:
Day 0 2 x 10^7 cells/m2 Day 14 2 x 10^7 cells/m2
Group Two:
Day 0 6 x 10^7 cells/m2 Day 14 6 x 10^7 cells/m2
Group Three:
Day 0 1.5 x 10^8 cells/m2 Day 14 1.5 x 10^8 cells/m2</description>
    <arm_group_label>TGFbeta resistant LMP-specific CTLs</arm_group_label>
    <other_name>TGF-b Resistant LMP2A-Specific Cytotoxic T-Lymphocytes</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        INCLUSION CRITERIA:

          1. Any patient, regardless of age or sex, with EBV-positive lymphoma, or
             lymphoepithelioma regardless of the histological subtype or EBV (associated)-T/NK-LPD
             all confirmed on any tissue sample.

             Primary refractory lymphoma or in second or subsequent relapse including after
             autologous or syngeneic stem cell transplant OR patients at a high risk for relapse
             defined as: (i) patients with primary refractory lymphoma or multiply relapsed
             lymphoma who are in remission but not eligible for autologous SCT or (ii) patients
             with relapsed lymphoma after autologous SCT who are in remission but not eligible for
             allogeneic SCT (Group A)

             OR

             Any patient who has received an allogeneic SCT for EBV Lymphoma or EBV
             (associated)-T/NK-LPD or Lymphoepithelioma (Group B)

          2. Patients with life expectancy 6 weeks or greater from the time of CTL infusion.

          3. Patients with a Karnofsky score of 50 or greater.

          4. If post allogeneic SCT must not have less than 50% donor chimerism in either
             peripheral blood or bone marrow

          5. Patients with bilirubin 3x normal or less, AST 5x normal or less, and Hgb greater than
             8.0

          6. Patients with a creatinine 2x normal for age or less

          7. Patients with O2 saturations greater than 93% on room air (measured by pulse oximetry)

          8. Patient, parent/guardian able to give informed consent.

          9. Patients should have been off other investigational therapy for one month prior to
             entry in this study.

        EXCLUSION CRITERIA:

          1. Patients with a severe intercurrent infection.

          2. Patients with evidence of GVHD greater than Grade II at time of enrollment.

          3. HIV positive at time of procurement cells for CTL generation

          4. Due to unknown effects of this therapy on a fetus, pregnant women are excluded from
             this research. The male partner should use a condom.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Helen E Heslop, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Baylor College of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Houston Methodist Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Childrens Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 22, 2006</study_first_submitted>
  <study_first_submitted_qc>August 22, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 24, 2006</study_first_posted>
  <last_update_submitted>October 27, 2017</last_update_submitted>
  <last_update_submitted_qc>October 27, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 31, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Baylor College of Medicine</investigator_affiliation>
    <investigator_full_name>Helen Heslop</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>EBV-Positive Lymphoma</keyword>
  <keyword>HodgkinÂ´s Disease (HD)</keyword>
  <keyword>Non-Hodgkin's lymphoma (NHL)</keyword>
  <keyword>relapsed Hodgkin's disease</keyword>
  <keyword>relapsed non-Hodgkin's disease</keyword>
  <keyword>lymphoma</keyword>
  <keyword>TGFbeta resistant LMP-specific CTLs</keyword>
  <keyword>cytotoxic T cells</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Hodgkin Disease</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

